These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27044549)

  • 1. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
    Matzneller P; Lackner E; Lagler H; Wulkersdorfer B; Österreicher Z; Zeitlinger M
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3617-25. PubMed ID: 27044549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.
    Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
    Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
    J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
    Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
    Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an
    Edlinger-Stanger M; Al Jalali V; Andreas M; Jäger W; Böhmdorfer M; Zeitlinger M; Hutschala D
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0067921. PubMed ID: 34280013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.
    Riccobene TA; Su SF; Rank D
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
    Cheng K; Pypstra R; Yan JL; Hammond J
    J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J; Das S; Zhou D; Al-Huniti N
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Hammel JP; Van Wart SA; Rubino CM; Reynolds DK; Forrest A; Khariton T; Friedland HD; Riccobene TA; Ambrose PG
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6348-50. PubMed ID: 24041902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
    Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
    Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
    Riccobene TA; Pushkin R; Jandourek A; Knebel W; Khariton T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5849-57. PubMed ID: 27431215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.
    Minichmayr IK; Wicha SG; Matzneller P; Kloft C; Zeitlinger M
    Clin Pharmacokinet; 2024 Jan; 63(1):121-131. PubMed ID: 38007714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
    Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
    J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study.
    Al Jalali V; Wölfl-Duchek M; Taubert M; Matzneller P; Lackner E; Dorn C; Kratzer A; Wulkersdorfer B; Österreicher Z; Zeitlinger M
    J Antimicrob Chemother; 2021 Aug; 76(9):2342-2351. PubMed ID: 34050650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
    Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.
    Matzneller P; Österreicher Z; Reiter B; Lackner E; Stimpfl T; Zeitlinger M
    J Antimicrob Chemother; 2016 Nov; 71(11):3179-3184. PubMed ID: 27494910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.